Targeting specific kinase substrates rescues increased colitis severity induced by the Crohn’s disease–linked LRRK2-N2081D variant
Authors:
- George R. HeatonGHGeorge R. Heaton
- Xingjian LiXLXingjian Li
- Xianting LiXLXianting Li
- Xiaoting ZhouXZXiaoting Zhou
- Yuanxi ZhangYZYuanxi Zhang
- Duc Tung VuDVDuc Tung Vu
- Marc OellerMOMarc Oeller
- Ozge KarayelOKOzge Karayel
- Quyen Q. HoangQHQuyen Q. Hoang
- Meltem Ece KarsMKMeltem Ece Kars
- Nitika KamathNKNitika Kamath
- Minghui WangMWMinghui Wang
Open Access
- 1 October 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Abstract
LRRK2 contains a kinase domain where the N2081D Crohn’s disease (CD) risk and the G2019S Parkinson’s disease (PD) pathogenic variants are located. It is not clear how the N2081D variant increases CD risk or how these adjacent mutations give rise to distinct disorders. To investigate the pathophysiology of the CD-linked LRRK2 N2081D variant, we generated a knock-in (KI) mouse model and compared its effects with those of the LRRK2-G2019S mutation. Lrrk2 N2081D KI mice demonstrated heightened sensitivity to induced colitis, resulting in more severe intestinal damage than in Lrrk2 G2019S KI and WT mice. Analysis of colon tissue revealed distinct mutation-dependent LRRK2 RAB substrate phosphorylation, with significantly elevated phosphorylated RAB10 levels in Lrrk2 N2081D mice. In cells, we demonstrated that the N2081D mutation activates LRRK2 through a mechanism distinct from that of LRRK2-G2019S. We also found that proinflammatory stimulation enhances LRRK2 kinase activity, leading to mutation-dependent differences in RAB phosphorylation and inflammatory responses in dendritic cells (DCs). Finally, we show that knockout of Rab12 , but not pharmacological LRRK2 kinase inhibition, significantly reduced colitis severity in Lrrk2 N2081D mice. Our study characterizes the pathogenic mechanisms of LRRK2-linked CD, highlights structural and functional differences between disease-associated LRRK2 variants, and suggests RAB proteins as promising therapeutic targets for modulating LRRK2 activity in CD treatment.Keywords
All Related Versions
Funding Information
- Michael J. Fox Foundation for Parkinson’s Research (MJFF #18661,MJFF #15066))
- National Institute of Neurological Disorders and Stroke (P20NS123220)
- New York Community Trust (P23-000586)
This publication has 45 references indexed in Scilit:
- MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionThe Journal of Pharmacology and Experimental Therapeutics, 2015
- A global reference for human genetic variationNature, 2015
- The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel diseaseNature Immunology, 2011
- Intestinal dendritic cells in the pathogenesis of inflammatory bowel diseaseWorld Journal of Gastroenterology, 2011
- METAL: fast and efficient meta-analysis of genomewide association scansBioinformatics, 2010
- Fast model-based estimation of ancestry in unrelated individualsGenome Research, 2009
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- The Role of Dendritic Cells in the Development of Acute Dextran Sulfate Sodium ColitisThe Journal of Immunology, 2007
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004